Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study | Zendy

Weerawat Manosuthi | Zendy; Preecha Tantanathip | Zendy; Sukanya Chimsuntorn | Zendy; Boonchuay Eampokarap | Zendy; Supeda Thongyen | Zendy; Samruay Nilkamhang | Zendy; Somnuek Sungkanuparph | Zendy

Open Access

Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study

Author(s) -

Weerawat Manosuthi,

Preecha Tantanathip,

Sukanya Chimsuntorn,

Boonchuay Eampokarap,

Supeda Thongyen,

Samruay Nilkamhang,

Somnuek Sungkanuparph

Publication year - 2010

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2010.06.016

Subject(s) - nevirapine , medicine , interquartile range , tuberculosis , discontinuation , regimen , odds ratio , rifampicin , coinfection , confidence interval , human immunodeficiency virus (hiv) , gastroenterology , viral load , surgery , antiretroviral therapy , immunology , pathology

The concurrent use of nevirapine-based antiretroviral therapy (ART) and rifampin-containing anti-tuberculosis regimens for the treatment of HIV and tuberculosis (TB) is common in resource-limited countries. Long-term outcomes of this concurrent treatment are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research